Julia DeVillers wants to reduce the stigma of anal cancer. “Women get it. Men get it ... It’s all directly related to getting ...

A weekly symptom-assessment intervention led by trained lay health workers may help reduce acute care use and improve ...

AbbVie’s telisotuzumab adizutecan achieved an ORR of 63% in EGFR-mutant NSCLC patients, with current ADC options in this population lacking.

Hecht, MD, discusses the phase 3 OrigAMI-3 trial for patients with recurrent, unresectable, or metastatic RAS/BRAF wild-type colorectal cancer.

EVERYONE’S talking about fat jabs – the ‘miracle’ injections trimming inches off waistlines, and helping turn the tide on the ...

The addition of postsurgical atezolizumab immunotherapy to standard-of-care chemotherapy in patients with stage III deficient ...

The MUHC Foundation's signature gala, Le Bal Rouge, brought together Montreal's most passionate changemakers in business, philanthropy and health care to celebrate a decade of innovation at the McGill ...

Cuts in NIH grants and the threat of more are discouraging investment and may drive trials out of the United States.

Amgen Inc. (NASDAQ: AMGN )’s thrombocytopenia drug Nplate (romiplostim) showed significant benefits in a Phase III trial for ...

Alphamab Oncology (stock code: 9966.HK) announced that multiple clinical data updates for anti-HER2 biparatopic antibody-drug conjugate (ADC) JSKN003 were presented as posters at the 2025 Annual ...

According to the 2022 national cancer registration statistics, the number of gastric cancer patients was 356,507, accounting ...

Seventy-three percent of patients with breast and other solid tumors did not experience ILD recurrence when rechallenged with ...